Abstract
AR-121 (Nystatin(LF,TM), i.v.) is an intravenous formulation of nystatin, an established oral and topical antifungal. Toxicity of nystatin has precluded its intravenous administration as a therapy for systemic fungal infections. Our studies indicate that AR-121 is less toxic than free nystatin, allowing the administration of higher doses effective in treatment of murine candidiasis, a common systemic fungal infection. Pharmaceutical development and clinical trials of AR-121 are being carried out by Argus Pharmaceuticals Inc. (Woodlands, Texas).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 724-730 |
| Number of pages | 7 |
| Journal | Drugs of the Future |
| Volume | 19 |
| Issue number | 8 |
| DOIs | |
| State | Published - 1994 |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)